By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell products developer Stemgent said today that it has started a new business in Scotland that will develop reagents and kits and offer services for use in studying the ubiquitin proteasome pathway (UPP) for drug research.

Stemgent, which has operations in Boston and San Diego, will invest roughly $4.5 million over three years in the new venture, which is based in Dundee.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.